A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This is a dose and schedule finding study of AMG 531 designed to assess the activity of AMG
531 to reduce the rate of clinically significant bleeding and blood transfusions in subjects
with myelodysplastic syndrome (MDS) receiving lenalidomide. Subjects with MDS that are
planned to receive at least four cycles of lenalidomide for treatment of their disease are
appropriate to screen for this study.
All subjects meeting the eligibility criteria will receive lenalidomide 10 mg capsule by
mouth daily every day of each 28-day cycle. Subjects will receive AMG 531 or placebo once a
week by subcutaneous injection for 16 weeks.